Breast Cancer | Specialty

The OncLive Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.


ESR1 Data Fuel Novel Breast Cancer Strategies

March 15th 2022

Mutations on the ESR1 gene, which encodes the estrogen receptor, have emerged as an important driver of resistance to endocrine therapies, which form the backbone of treatment for patients with ER-positive, HER2-negative breast cancer.

Amcenestrant Misses PFS End Point in ER+/HER2– Advanced or Metastatic Breast Cancer

March 14th 2022

Amcenestrant did not improve progression-free survival per independent central review vs physician’s choice of endocrine treatment in select patients with locally advanced or metastatic, estrogen receptor–positive, HER2-negative breast cancer, missing the primary end point of the phase 2 AMEERA-3 trial.

Dr. Bardia on the Rationale of Utilizing Endocrine Therapy in ER+ Breast Cancer

March 14th 2022

Aditya Bardia, MD, MPH, discusses the use of endocrine therapy in estrogen receptor–positive breast cancer.

Dr. Davidson on the Future of HER2-Targeted Therapies in Breast Cancer

March 14th 2022

Nancy E. Davidson, MD, discusses the future of HER2-targeted therapies in breast cancer.

Breast Cancer Management Grows With Innovative, Better Tailored Treatment

March 13th 2022

The historical boundaries of what was possible in the management of patients with breast cancer continue to be challenged, evidenced by the use of HER2-directed therapies in patients with brain metastases, de-escalated approaches in patients with visceral disease, and less-invasive surgical techniques for patients with lymph node involvement.

FDA Approves Adjuvant Olaparib for BRCA+, High-Risk Early Breast Cancer

March 11th 2022

The FDA has approved olaparib for the adjuvant treatment of patients with germline BRCA-mutated, HER2-negative, high-risk early breast cancer who have previously received chemotherapy either before or after surgery.

Biomarkers of Response Steer Treatment Selection in Breast Cancer

March 11th 2022

Tiffany Traina, MD, discusses the body of evidence supporting the use of CDK4/6 inhibitors in hormone receptor–positive, HER2-negative breast cancer, shifting standards of care in HER2-positive disease, as well as biomarkers of response with checkpoint inhibitors and PARP inhibitors in triple-negative breast cancer.

Safety and Efficacy of Tucatinib–Trastuzumab-Capecitabine Regimen for Treatment of Leptomeningeal Metastasis in HER2+ Breast Cancer: Results from TBCRC049, A Phase 2 Non-Randomized Study

March 11th 2022

Dr. Tripathy reviews the safety and efficacy data from a phase 2 non-randomized study of tucatinib-trastuzumab-capecitabine regimen in patients with leptomeningeal metastasis.

Evolving Treatment Landscape of HER2+ Metastatic Breast Cancer

March 10th 2022

Closing out their discussion on novel therapies for HER2+ metastatic breast cancer, experts share excitement for future clinical trials and strategies.

NEJM Data Underscore OS Benefit With Ribociclib/Letrozole in HR+ Advanced Breast Cancer

March 10th 2022

The combination of ribociclib and letrozole resulted in a statistically significant improvement in overall survival vs letrozole alone in patients with postmenopausal, hormone receptor–positive, HER2-negative advanced breast cancer, with this benefit continuing to increase over time, supporting the use of this combination as a frontline treatment in this population.

Dr. Hurvitz on the Benefit of Trastuzumab Deruxtecan in HER2+ Breast Cancer with Brain Metastases

March 9th 2022

Sara A. Hurvitz, MD, discusses the benefit of trastuzumab deruxtecan in a subset of patients with HER2-positive breast cancer and active brain metastases in the phase 3 DESTINY-Breast03 trial.

Dr. Tolaney on Pivotal Trials in HER2+ Breast Cancer

March 9th 2022

Sara M. Tolaney, MD, MPH, discusses pivotal trials in HER2-positive breast cancer.

NICE Rejects Pembrolizumab Plus Chemotherapy for Select Metastatic TNBC

March 9th 2022

The United Kingdom’s National Institute for Health and Clinical Excellence has issued draft guidance recommending against pembrolizumab plus chemotherapy as a treatment for patients with metastatic triple-negative breast cancer whose tumors express PD-L1 with a combined positive score of 10 or more and who have not received chemotherapy for metastatic disease.

Talazoparib Shows Real-World Clinical Benefit in Germline BRCA-Mutated, HER2-Negative, Advanced Breast Cancer

March 9th 2022

Clinical outcomes achieved with talazoparib in a real-world population of patients with HER2-negative, locally advanced or metastatic breast cancer harboring germline BRCA mutations proved to be consistent with those observed in the phase 3 EMBRACA trial.

Institutional Perspectives in Cancer- Breast Cancer: Chaired by Harold J. Burstein, MD, PhD & Sara M. Tolaney, MD, MPH

March 9th 2022

Dr. Hurvitz on the Clinical Implications of the DESTINY-Breast03 Trial in HER2+ Breast Cancer

March 8th 2022

Sara A. Hurvitz, MD, discusses the clinical implications of the phase 3 DESTINY-Breast03 trial in HER2-positive breast cancer.

Optimizing Outcomes With ADCs in Breast Cancer Requires a Tactical Approach

March 8th 2022

Antibody-drug conjugates are innovative and effective therapeutic agents that have transformed the treatment landscape for patients with HER2-positive breast cancer and triple-negative breast cancer.

Sacituzumab Govitecan Significantly Improves PFS Vs Chemo in HR+ Metastatic Breast Cancer

March 7th 2022

Sacituzumab govitecan resulted in a statistically significant improvement in progression-free survival vs physician’s choice of chemotherapy in patients with hormone receptor–positive, HER2-negative metastatic breast cancer who previously received endocrine therapy, CDK4/6 inhibitors, and 2 to 4 lines of chemotherapy, meeting the primary end point of the phase 3 TROPiCS-02 trial.

Biomarkers Allow for Tailoring TNBC Treatments

March 5th 2022

Several factors aid treatment selection for patients with newly diagnosed metastatic triple-negative breast cancer, with upfront PD-L1 and BRCA testing being the most critical biomarkers to examine.

Abemaciclib/Endocrine Therapy Combo Showcases Long-Term Clinical Benefit in HR+ High-Risk Early Breast Cancer

March 5th 2022

The combination of adjuvant abemaciclib and endocrine therapy led to a clinically meaningful benefit at 3 years in patients with hormone receptor–positive, HER2-negative, node-positive, early breast cancer.